Breaking News, Financial News

Financial Report: AMRI

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

2Q Revenues: $45.6 million (-12%)

2Q Loss: $353,000* (earnings were $7.3 million in 2Q2005)

YTD Revenues: $88.9 million (-12%)

YTD Earnings: $1.5 million (earnings were $12.9 million YTD2005)

Comments: Revenue for Discovery Services in the second quarter was $9.4 million, up 48%. Revenue from Development and Small Scale Manufacturing in the quarter was $8.2 million, up 17%. Large Scale Manufacturing revenues were $20.8 million, down 8%. Royalties from Allegra were down 55% to $7.2 million, due to generic competition.

*Earnings for the quarter reflect an impairment charge of $2.2 million related to Mount Prospect Research Center.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters